리세르가미데스속
Lysergamides리세르긴산의 아미드는 집합적으로 리세르가미드로 알려져 있으며, 다양한 세로토닌 [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]수용체 및 도파민 수용체에서 강력한 작용제 및/또는 길항제 활성을 가진 다수의 화합물을 포함한다.
구조. | 이름. | CAS 번호 | R1 | R6 | R2 | R3 | 다른. |
---|---|---|---|---|---|---|---|
LSA/LAA | 478-94-4 | H | CH3 | H | H | - | |
DAM-57 | 4238-84-0 | H | CH3 | CH3 | CH3 | - | |
에르고메트린(에르고노빈) | 60-79-7 | H | CH3 | CH(CH32) CHOH | H | - | |
에르고타민 | 113-15-5 | H | CH3 | -- | 채널171824 | - | |
메테르기네 | 113-42-8 | H | CH3 | CH(CH23) CHOH2 | H | - | |
메티세르기드 | 361-37-5 | CH3 | CH3 | CH(CH23) CHOH2 | H | - | |
아메세르기드 | 121588-75-8 | CH(CH3)2 | CH3 | C6H11 | H | - | |
LY-215840 | 137328-52-0 | CH(CH3)2 | CH3 | 쵸우58 | H | - | |
카베르골린 | 81409-90-7 | H | HC2=CH-CH2 | 콘치23 | CHCHN222(CH3)2 | - | |
LAE-32 | 478-99-9 | H | CH3 | CHH23 | H | - | |
LAiP | H | CH3 | CH(CH3)2 | H | - | ||
LAtB | H | CH3 | C(CH3)3 | H | - | ||
LAcB | H | CH3 | (CH2)4 | H | - | ||
세펜틸 | H | CH3 | (CH2)5 | H | - | ||
LSB | 137765-82-3 | H | CH3 | CH(CH3)CH23 | H | - | |
LSP | H | CH3 | CH(CH23)CH23 | H | - | ||
달. | H | CH3 | HC2=CH-CH2 | HC2=CH-CH2 | - | ||
MIPLA | 100768-08-9 | H | CH3 | CH(CH3)2 | CH3 | - | |
EIPA | H | CH3 | CH(CH3)2 | CHH23 | - | ||
에코프라 | H | CH3 | C3H5 | CHH23 | - | ||
엣펠라 | H | CH3 | CH2CF3 | CHH23 | - | ||
램프 | 40158-98-3 | H | CH3 | CHACH223 | CH3 | - | |
EPLA | H | CHH23 | CHACH223 | CH3 | - | ||
LSD/LAD | 50-37-3 | H | CH3 | CHH23 | CHH23 | - | |
ETH-LAD | 65527-62-0 | H | CHH23 | CHH23 | CHH23 | - | |
패리티 레이드 | H | HCcC-CH2 | CHH23 | CHH23 | - | ||
알-라드 | 65527-61-9 | H | HC2=CH-CH2 | CHH23 | CHH23 | - | |
프로레이드 | 65527-63-1 | H | CHACH223 | CHH23 | CHH23 | - | |
IP-LAD | H | CH(CH3)2 | CHH23 | CHH23 | - | ||
CYP-LAD | H | C3H5 | CHH23 | CHH23 | - | ||
부라드 | 96930-87-9 | H | 챠치2223 | CHH23 | CHH23 | - | |
투시판[16] | H | CHF22 | CHH23 | CHH23 | - | ||
ALD-52 | 3270-02-8 | 코치3 | CH3 | CHH23 | CHH23 | - | |
1P-LSD | 2349358-81-0 | 코치23 | CH3 | CHH23 | CHH23 | - | |
1B-LSD | 2349376-12-9 | 코치223 | CH3 | CHH23 | CHH23 | - | |
1V-LSD | CO(CH2)3CH3 | CH3 | CHH23 | CHH23 | - | ||
1cP-LSD[17] | 코치35 | CH3 | CHH23 | CHH23 | - | ||
1cP-AL-LAD | 코치35 | HC2=CH-CH2 | CHH23 | CHH23 | - | ||
1P-ETH-LAD | 코치23 | CHH23 | CHH23 | CHH23 | - | ||
1P-MIPLA | 코치23 | CH3 | CH(CH3)2 | CH3 | - | ||
MLD-41 | 4238-85-1 | CH3 | CH3 | CHH23 | CHH23 | - | |
LSM-775 | 4314-63-0 | H | CH3 | CH-O-CH-CH2222 | - | ||
LPD-824 | 2385-87-7 | H | CH3 | (CH2)4 | - | ||
LSD-PIP | 50485-23-9 | H | CH3 | (CH2)5 | - | ||
LSD-Azapane | H | CH3 | (CH2)6 | - | |||
LA-SS-Az | 470666-31-0 | H | CH3 | CH2(CH3)2CH2 | - | ||
2-Broomo-LSD | 478-84-2 | H | CH3 | CHH23 | CHH23 | 2-Br | |
12-메톡시-LSD[18] | 50484-99-6 | H | CH3 | CHH23 | CHH23 | 12-OME | |
14-히드록시-LSD[19] | H | CH3 | CHH23 | CHH23 | 14-OH |
「 」를 참조해 주세요.
레퍼런스
- ^ Hofmann A (June 1959). "Psychotomimetic drugs; chemical and pharmacological aspects". Acta Physiologica et Pharmacologica Neerlandica. 8: 240–58. PMID 13852489.
- ^ 미국 특허 2997470, Pioch RP, "LYSERGIC ACIDES", 1956-03-05, 1961-08-22 발행
- ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.
- ^ Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (March 1994). "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior. 47 (3): 667–673. doi:10.1016/0091-3057(94)90172-4. PMID 8208787.
- ^ Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–409. doi:10.1007/BF02245940. PMID 7568626.
- ^ Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–4349. doi:10.1021/jm020153s. PMID 12213075.
- ^ Schiff PL (October 2006). "Ergot and its alkaloids". American Journal of Pharmaceutical Education. 70 (5): 98. doi:10.5688/aj700598. PMID 17149427.
- ^ Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. "The pharmacology of lysergic acid diethylamide: a review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.
- ^ Nichols DE. "Chemistry and Structure-Activity Relationships of Psychedelics". Current Topics in Behavioral Neurosciences. 36: 1–43. doi:10.1007/7854_2017_475. PMID 28401524.
- ^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, et al. (September 2016). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)". Drug Testing and Analysis. 8 (9): 891–902. doi:10.1002/dta.1884. PMID 26456305.
- ^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi:10.1002/dta.1985. PMID 27265891.
- ^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, et al. (October 2017). "Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)". Drug Testing and Analysis. 9 (10): 1641–1649. doi:10.1002/dta.2196. PMID 28342178.
- ^ Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, et al. (February 2018). "Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)". Drug Testing and Analysis. 10 (2): 310–322. doi:10.1002/dta.2222. PMID 28585392.
- ^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, et al. (August 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)". Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. PMID 31083768.
- ^ Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5055-9. PMID 30298278.
- ^ WO 2022/008627, 그릴 M, "리세르그산 디에틸아미드(LSD) 제조 방법 및 신규 유도체 개선"
- ^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, et al. (June 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. PMID 32180350.
- ^ Usdin E, Efron DH. 향정신성 의약품 및 관련 화합물(1972) ASIN B002X3CDIY
- ^ Libânio Osório Marta RF (August 2019). "Metabolism of lysergic acid diethylamide (LSD): an update". Drug Metabolism Reviews. 51 (3): 378–387. doi:10.1080/03602532.2019.1638931. PMID 31266388.